Hyperthermic IntraVEsical Chemotherapy

Patient (N=339) Intermediate risk
NMIBC
TURB and 1 instillation MMC.
Screened, Consented Randomised
Hyperthermia 30 mins +
Mitomycin C 40 mg
Once weekly for 4 weeks
Once monthly for 3 months
Hyperthermia 60 mins +
Mitomycin C 40mg
Once weekly for 4 weeks
Once monthly for 3 month

Mitomycin C 40mg

Once weekly for 4 weeks
Once monthly for 3 months

Year 1: 4-monthly surveillance for disease recurrence.
Year 2: 6-monthly surveillance for disease recurrence to 24 months
Disease free survival

24 Months Follow Up
PEP: Disease Free Time, SEP: Recurrence Rate, Tolerance, QoL